Treffer: Cerebral Protection Devices in Case of Left Sided Intracardiac Thrombus: A Multicentre Experience From the Cath Lab and EP Lab.
D. R. Holmes, S. Kar, M. J. Price, et al., “Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long‐Term Warfarin Therapy,” Journal of the American College of Cardiology 64 (2014): 1–12.
D. Patel, S. M. Bailey, A. J. Furlan, et al., “Long‐Term Functional and Neurocognitive Recovery in Patients Who Had an Acute Cerebrovascular Event Secondary to Catheter Ablation for Atrial Fibrillation,” Journal of Cardiovascular Electrophysiology 21 (2010): 412–417.
R. Cappato, H. Calkins, S. A. Chen, et al., “Updated Worldwide Survey on the Methods, Efficacy, and Safety of Catheter Ablation for Human Atrial Fibrillation,” Circulation: Arrhythmia and Electrophysiology 3 (2010): 32–38.
P. Santangeli, L. Di Biase, R. Horton, et al., “Ablation of Atrial Fibrillation Under Therapeutic Warfarin Reduces Periprocedural Complications Evidence From a Meta‐Analysis,” Circulation: Arrhythmia and Electrophysiology 5 (2012): 302–311.
M. Bohnen, W. G. Stevenson, U. B. Tedrow, et al., “Incidence and Predictors of Major Complications From Contemporary Catheter Ablation to Treat Cardiac Arrhythmias,” Heart Rhythm: The Official Journal of the Heart Rhythm Society 8 (2011): 1661–1666, https://doi.org/10.1016/j.hrthm.2011.05.017.
K. H. Kuck, A. Schaumann, L. Eckardt, et al., “Catheter Ablation of Stable Ventricular Tachycardia Before Defibrillator Implantation in Patients With Coronary Heart Disease (Vtach): A Multicentre Randomised Controlled Trial,” Lancet 375 (2010): 31–40, https://doi.org/10.1016/S0140-6736(09)61755-4.
I. R. Whitman, R. A. Gladstone, N. Badhwar, et al., “Brain Emboli After Left Ventricular Endocardial Ablation,” Circulation 135 (2017): 867–877.
S. R. Kapadia, S. Kodali, R. Makkar, et al., “Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement,” Journal of the American College of Cardiology 69 (2017): 367–377.
S. Haussig, N. Mangner, M. G. Dwyer, et al., “Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The Clean‐Tavi Randomized Clinical Trial,” Journal of the American Medical Association 316 (2016): 592–601.
T. M. Nazif, J. Moses, R. Sharma, et al., “Randomized Evaluation of Triguard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement,” JACC: Cardiovascular Interventions 14 (2021): 515–527.
J. Seeger, B. Gonska, M. Otto, W. Rottbauer, and J. Wöhrle, “Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures,” JACC: Cardiovascular Interventions 10 (2017): 2297–2303.
J. Seeger, S. R. Kapadia, S. Kodali, et al., “Rate of Peri‐Procedural Stroke Observed With Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: A Patient‐Level Propensity‐Matched Analysis,” European Heart Journal 40 (2019): 1334–1340, https://doi.org/10.1093/eurheartj/ehy847.
P. M. Ndunda, M. R. Vindhyal, T. M. Muutu, and Z. Fanari, “Clinical Outcomes of Sentinel Cerebral Protection System Use During Transcatheter Aortic Valve Replacement: A Systematic Review and Meta‐Analysis,” Cardiovascular Revascularization Medicine 21 (2020): 717–722.
D. Zachariah, L. R. Limite, P. Mazzone, et al., “Use of Cerebral Protection Device in Patients Undergoing Ventricular Tachycardia Catheter Ablation,” JACC: Clinical Electrophysiology 8 (2022): 528–530.
C. H. Heeger, A. Metzner, M. Schlüter, et al., “Cerebral Protection During Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Heart Disease,” Journal of the American Heart Association 7, no. 13 (2018): e009005.
L. R. Limite, A. Radinovic, L. Cianfanelli, et al., “Outcome of Left Atrial Appendage Closure Using Cerebral Protection System for Thrombosis: No Patient Left Behind,” Pacing and Clinical Electrophysiology 45 (2022): 23–34.
G. G. Boccuzzi, A. Montabone, F. D'Ascenzo, et al., “Cerebral Protection in Left Atrial Appendage Closure in the Presence of Appendage Thrombosis,” Catheterization and Cardiovascular Interventions 97 (2021): 511–515.
J. Berg, A. Preda, N. Fierro, et al., “A Referral Center Experience With Cerebral Protection Devices: Challenging Cardiac Thrombus in the EP Lab,” Journal of Clinical Medicine 12 (2023): 1549.
B. S. Lowe, K. Kusunose, H. Motoki, et al., “Prognostic Significance of Left Atrial Appendage”Sludge” in Patients With Atrial Fibrillation: A New Transesophageal Echocardiographic Thromboembolic Risk Factor,” Journal of the American Society of Echocardiography 27 (2014): 1176–1183, https://doi.org/10.1016/j.echo.2014.08.016.
D. Zachariah, K. Nakajima, L. R. Limite, et al., “Significance of Abnormal and Late Ventricular Signatures in Ventricular Tachycardia Ablation of Ischaemic and Non‐Ischaemic Cardiomyopathies,” Heart Rhythm 19 (2022): 2075–2083, https://linkinghub.elsevier.com/retrieve/pii/S1547527122022937.
S. P. Sharma, J. Cheng, M. K. Turagam, et al., “Feasibility of Left Atrial Appendage Occlusion in Left Atrial Appendage Thrombus,” JACC: Clinical Electrophysiology 6 (2020): 414–424.
S. R. Kapadia, R. Makkar, M. Leon, et al., “Cerebral Embolic Protection During Transcatheter Aortic‐Valve Replacement,” New England Journal of Medicine 387 (2022): 1253–1263.
N. M. Butala, S. R. Kapadia, E. A. Secemsky, et al., “Impact of Cerebral Embolic Protection Devices on Disabling Stroke After TAVR: Updated Results From the STS/ACC TVT Registry,” Circulation. Cardiovascular Interventions 17 (2024): 013697, https://doi.org/10.1161/CIRCINTERVENTIONS.123.013697.
Weitere Informationen
Background: Performing a left atrial appendage occlusion (LAAO) or catheter ablation with left-sided intracardiac thrombus is considered very-high risk for periinterventional stroke. Cerebral embolic protection (CEP) devices are designed to prevent cardioembolic stroke and have been widely studied in TAVR procedures. However, their role in LAAO and catheter ablation of ventricular tachycardia (VT) or in pulmonary vein isolation (PVI) with cardiac thrombus present remains unknown.
Purpose: to study utility and safety of CEP devices during LAAO and catheter ablation in patients with left sided intracardiac thrombus in a multicenter setting.
Methods: Two different CEP devices were used according to the physician's discretion: (1) a capture device consisting of two filters for the brachiocephalic and left common carotid arteries placed from a radial artery; or (2) a deflection device covering all three supra-aortic vessels placed over a femoral artery. Periprocedural and safety data from 2019 to 2023 were retrospectively obtained from procedural reports and discharge letters for all patients with left-sided intracardiac thrombus undergoing LAAO, VT ablation, or PVI under protection with a CEP device. Long-term safety data were obtained by clinical follow-up in the respective institutions and telephone consultations.
Results: Sixty-five patients were enrolled in five centers in Italy. Fifty-two patients underwent LAA closure, 12 patients underwent VT ablation and one patient underwent PVI. Mean age was 73 ± 10 years and 43 (66%) were male, mean LVEF was 46 ± 13%. The location of the cardiac thrombus was the LAA in all 52 patients (100%) undergoing LAA closure whereas in patients undergoing VT ablation, thrombus was present in the LAA in five cases (42%), left ventricle (n = 6; 50%) and aortic arch (n = 1;8%). One patient developed left atrial thrombus during PVI. The capture device was used in 39 out of 65 (60%) and the deflection device in 26 out of 65 cases (40%). There were no periprocedural strokes or transitory ischemic attacks (TIA). CEP-related complications at the arterial access site were noted in 4 cases (6%) and were minor, not requiring surgery. Other periprocedural events were one transient ST-elevation caused by coronary spasm in a patient undergoing LAA closure, not related to the CEP device. There was one in-hospital death after VT ablation due to cardiogenic shock, not related to the CEP device. At long-term follow-up, one TIA and three non-cardiovascular deaths occurred with a mean follow-up time of 455 days.
Conclusions: This is the first multicentre experience showing that LAA closure or catheter ablation with cerebral protection in patients with cardiac thrombus is feasible without thromboembolic complications. The possibility of safely performing an intervention in this high-risk setting is promising and should be tested in a prospective randomized trial.
(© 2025 Wiley Periodicals LLC.)